Jordana E. Hoppe

605 total citations · 2 hit papers
24 papers, 256 citations indexed

About

Jordana E. Hoppe is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jordana E. Hoppe has authored 24 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 4 papers in Epidemiology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jordana E. Hoppe's work include Cystic Fibrosis Research Advances (21 papers), Neonatal Respiratory Health Research (11 papers) and Tracheal and airway disorders (10 papers). Jordana E. Hoppe is often cited by papers focused on Cystic Fibrosis Research Advances (21 papers), Neonatal Respiratory Health Research (11 papers) and Tracheal and airway disorders (10 papers). Jordana E. Hoppe collaborates with scholars based in United States, Germany and Canada. Jordana E. Hoppe's co-authors include Edith T. Zemanick, Scott D. Sagel, Brandie D. Wagner, Frank J. Accurso, Stacey L. Martiniano, Margaret Rosenfeld, Jennifer L. Taylor‐Cousar, Neil Ahluwalia, Anna Chin and Mengdi Lu and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, The Lancet Respiratory Medicine and Pediatric Pulmonology.

In The Last Decade

Jordana E. Hoppe

21 papers receiving 253 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

2023 74 citations Jennifer L. Goralski, Jordana E. Hoppe et al. American Journal of Respiratory and Critical Care Medicine profile →
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

2025 22 citations Jordana E. Hoppe, Ajay S. Kasi et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jordana E. Hoppe United States	9	222	28	27	23	17	24	256
Jill M. VanDalfsen United States	8	316 1.4×	5 0.2×	33 1.2×	17 0.7×	21 1.2×	11	335
Peter J. Wills United Kingdom	10	368 1.7×	4 0.1×	73 2.7×	27 1.2×	85 5.0×	13	423
Sandra Scott United Kingdom	9	382 1.7×	5 0.2×	31 1.1×	19 0.8×	89 5.2×	10	437
Dave P. Nichols United States	8	190 0.9×	2 0.1×	49 1.8×	12 0.5×	23 1.4×	11	223
Bonnie Dasgupta Canada	6	356 1.6×	2 0.1×	32 1.2×	21 0.9×	53 3.1×	7	387
Karl Holden United Kingdom	6	138 0.6×	5 0.2×	9 0.3×	25 1.1×	137 8.1×	9	201
Katrina O. Tonga Australia	10	177 0.8×	11 0.4×	13 0.5×	7 0.3×	133 7.8×	21	216
Natalia Cirilli Italy	11	236 1.1×	1 0.0×	37 1.4×	10 0.4×	24 1.4×	24	281
Suzanne W. J. Terheggen‐Lagro Netherlands	8	126 0.6×	1 0.0×	22 0.8×	10 0.4×	23 1.4×	21	244
Carolina Cisneros Spain	12	226 1.0×	2 0.1×	44 1.6×	12 0.5×	141 8.3×	33	296

Countries citing papers authored by Jordana E. Hoppe

Since Specialization

Citations

This map shows the geographic impact of Jordana E. Hoppe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordana E. Hoppe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordana E. Hoppe more than expected).

Fields of papers citing papers by Jordana E. Hoppe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordana E. Hoppe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordana E. Hoppe. The network helps show where Jordana E. Hoppe may publish in the future.

Co-authorship network of co-authors of Jordana E. Hoppe

This figure shows the co-authorship network connecting the top 25 collaborators of Jordana E. Hoppe. A scholar is included among the top collaborators of Jordana E. Hoppe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordana E. Hoppe. Jordana E. Hoppe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoppe, Jordana E., Ajay S. Kasi, Jessica E. Pittman, et al.. (2025). Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. The Lancet Respiratory Medicine. 13(3). 244–255. 22 indexed citations breakdown →

Hoppe, Jordana E., et al.. (2025). Impact of Home Collection and Shipping of Respiratory Specimens on Bacterial Pathogen Detection in Children With Cystic Fibrosis. Pediatric Pulmonology. 60(9). e71289–e71289.

Hoppe, Jordana E., J Sjöberg, Gina Hong, et al.. (2024). Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force. Journal of Cystic Fibrosis. 23(4). 725–733. 3 indexed citations

Mayer-Hamblett, Nicole, Alex H. Gifford, Margaret Kloster, et al.. (2024). Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Annals of the American Thoracic Society. 21(11). 1507–1515. 7 indexed citations

Martiniano, Stacey L., et al.. (2024). Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. Journal of Cystic Fibrosis. 24(3). 466–468. 7 indexed citations

Olson, Christina A., et al.. (2023). Case report: Cystic fibrosis with kwashiorkor: A rare presentation in the era of universal newborn screening. Frontiers in Pediatrics. 10. 1083155–1083155. 2 indexed citations

Goralski, Jennifer L., Jordana E. Hoppe, Marcus Mall, et al.. (2023). Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine. 208(1). 59–67. 74 indexed citations breakdown →

Sanders, Don B., Traci M. Bartz, Edith T. Zemanick, et al.. (2023). A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Annals of the American Thoracic Society. 20(12). 1769–1776. 4 indexed citations

Zemanick, Edith T., et al.. (2023). Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Review of Respiratory Medicine. 17(2). 97–108. 8 indexed citations

10.

Hamblett, N., Alex H. Gifford, Margaret Kloster, et al.. (2023). 106 Impact of discontinuing hypertonic saline and dornase alfa in people with cystic fibrosis established on elexacaftor-tezacaftor-ivacaftor: A SIMPLIFY ancillary study. Journal of Cystic Fibrosis. 22. S55–S56. 1 indexed citations

11.

Sagel, Scott D., Brandie D. Wagner, Stephanie D. Davis, et al.. (2022). Airway Inflammation in Children with Primary Ciliary Dyskinesia. Annals of the American Thoracic Society. 20(1). 67–74. 6 indexed citations

12.

Hoppe, Jordana E., Brandie D. Wagner, J. Kirk Harris, et al.. (2022). Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D. Journal of Cystic Fibrosis. 21(6). 950–958. 12 indexed citations

13.

Andrews, Ashley, et al.. (2021). Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatric Pulmonology. 56(7). 2043–2047. 12 indexed citations

14.

Hoppe, Jordana E., Brandie D. Wagner, Wayne J. Morgan, et al.. (2020). Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatric Pulmonology. 55(12). 3400–3406. 11 indexed citations

15.

Hoppe, Jordana E., Mark Chilvers, Félix Ratjen, et al.. (2020). WS19.2 Long-term safety of lumacaftor/ivacaftor therapy in persons with cystic fibrosis aged 2–5 years homozygous for the F508del-CFTR mutation (F/F). Journal of Cystic Fibrosis. 19. S31–S31. 1 indexed citations

16.

Hoppe, Jordana E., Brandie D. Wagner, Frank J. Accurso, Edith T. Zemanick, & Scott D. Sagel. (2018). Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis. 17(6). 760–768. 12 indexed citations

17.

Mueller, Jennifer L., Rashmi Murthy, Michael Capps, et al.. (2018). Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosis. Physiological Measurement. 39(4). 45008–45008. 30 indexed citations

18.

Hoppe, Jordana E., Brandie D. Wagner, Scott D. Sagel, Frank J. Accurso, & Edith T. Zemanick. (2017). Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulmonary Medicine. 17(1). 188–188. 6 indexed citations

19.

Hoppe, Jordana E., et al.. (2015). Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatric Pulmonology. 50(7). 638–646. 21 indexed citations

20.

Martiniano, Stacey L., Jordana E. Hoppe, Scott D. Sagel, & Edith T. Zemanick. (2014). Advances in the Diagnosis and Treatment of Cystic Fibrosis. Advances in Pediatrics. 61(1). 225–243. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact